- Home
- INGM vs NUVL Comparison
INGM vs NUVL Comparison
Compare INGM & NUVL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INGM
- NUVL
- Stock Information
- Founded
- INGM 1979
- NUVL 2017
- Country
- INGM United States
- NUVL United States
- Employees
- INGM N/A
- NUVL N/A
- Industry
- INGM
- NUVL Biotechnology: Pharmaceutical Preparations
- Sector
- INGM
- NUVL Health Care
- Exchange
- INGM NYSE
- NUVL Nasdaq
- Market Cap
- INGM 5.5B
- NUVL 5.6B
- IPO Year
- INGM 2024
- NUVL 2021
- Fundamental
- Price
- INGM $17.68
- NUVL $70.77
- Analyst Decision
- INGM Strong Buy
- NUVL Strong Buy
- Analyst Count
- INGM 14
- NUVL 10
- Target Price
- INGM $26.69
- NUVL $113.10
- AVG Volume (30 Days)
- INGM 505.0K
- NUVL 583.7K
- Earning Date
- INGM 03-04-2025
- NUVL 05-08-2025
- Dividend Yield
- INGM 0.41%
- NUVL N/A
- EPS Growth
- INGM N/A
- NUVL N/A
- EPS
- INGM 1.18
- NUVL N/A
- Revenue
- INGM $47,983,671,000.00
- NUVL N/A
- Revenue This Year
- INGM $5.37
- NUVL N/A
- Revenue Next Year
- INGM $3.78
- NUVL N/A
- P/E Ratio
- INGM $15.21
- NUVL N/A
- Revenue Growth
- INGM N/A
- NUVL N/A
- 52 Week Low
- INGM $17.75
- NUVL $61.80
- 52 Week High
- INGM $25.69
- NUVL $113.51
- Technical
- Relative Strength Index (RSI)
- INGM N/A
- NUVL 35.57
- Support Level
- INGM N/A
- NUVL $71.95
- Resistance Level
- INGM N/A
- NUVL $77.93
- Average True Range (ATR)
- INGM 0.00
- NUVL 3.04
- MACD
- INGM 0.00
- NUVL -0.16
- Stochastic Oscillator
- INGM 0.00
- NUVL 24.64
About INGM INGRAM MICRO HOLDING CORPORATION
Ingram Micro Holding Corp is a technology company for the global information technology ecosystem. It plays a vital role in the IT sales channel, bringing products and services from technology manufacturers and cloud providers to business-to-business technology experts. The company also provide a broad range of technology services, including financing, specialized marketing, and lifecycle management, as well as technical pre- and post-sales professional support.
About NUVL Nuvalent Inc.
Nuvalent Inc is a clinical stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically proven kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.